Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
ABSTRACTHuman gut microbiota are critical to both the development of and recovery from Clostridioides difficile infection (CDI). Antibiotics are the mainstay of CDI treatment, yet inherently cause further imbalances in the gut microbiota, termed dysbiosis, complicating recovery. A variety of microbi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2023.2223345 |
| _version_ | 1797236671169691648 |
|---|---|
| author | Anne J. Gonzales-Luna Travis J. Carlson Kevin W. Garey |
| author_facet | Anne J. Gonzales-Luna Travis J. Carlson Kevin W. Garey |
| author_sort | Anne J. Gonzales-Luna |
| collection | DOAJ |
| description | ABSTRACTHuman gut microbiota are critical to both the development of and recovery from Clostridioides difficile infection (CDI). Antibiotics are the mainstay of CDI treatment, yet inherently cause further imbalances in the gut microbiota, termed dysbiosis, complicating recovery. A variety of microbiota-based therapeutic approaches are in use or in development to limit disease- and treatment-associated dysbiosis and improve rates of sustained cure. These include the recently FDA-approved fecal microbiota, live-jslm (formerly RBX2660) and fecal microbiota spores, live-brpk (formerly SER−109), which represent a new class of live biotherapeutic products (LBPs), traditional fecal microbiota transplantation (FMT), and ultra-narrow-spectrum antibiotics. Here, we aim to review the microbiome changes associated with CDI as well as a variety of microbiota-based treatment approaches. |
| first_indexed | 2024-03-11T14:20:37Z |
| format | Article |
| id | doaj.art-a59465a6c63441e599d89c48b0075931 |
| institution | Directory Open Access Journal |
| issn | 1949-0976 1949-0984 |
| language | English |
| last_indexed | 2024-04-24T17:07:33Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj.art-a59465a6c63441e599d89c48b00759312024-03-28T22:38:20ZengTaylor & Francis GroupGut Microbes1949-09761949-09842023-12-0115110.1080/19490976.2023.2223345Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategiesAnne J. Gonzales-Luna0Travis J. Carlson1Kevin W. Garey2Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USADepartment of Clinical Sciences, High Point University Fred Wilson School of Pharmacy, High Point, NC, USADepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USAABSTRACTHuman gut microbiota are critical to both the development of and recovery from Clostridioides difficile infection (CDI). Antibiotics are the mainstay of CDI treatment, yet inherently cause further imbalances in the gut microbiota, termed dysbiosis, complicating recovery. A variety of microbiota-based therapeutic approaches are in use or in development to limit disease- and treatment-associated dysbiosis and improve rates of sustained cure. These include the recently FDA-approved fecal microbiota, live-jslm (formerly RBX2660) and fecal microbiota spores, live-brpk (formerly SER−109), which represent a new class of live biotherapeutic products (LBPs), traditional fecal microbiota transplantation (FMT), and ultra-narrow-spectrum antibiotics. Here, we aim to review the microbiome changes associated with CDI as well as a variety of microbiota-based treatment approaches.https://www.tandfonline.com/doi/10.1080/19490976.2023.2223345MicrobiomemicrobiotaClostridium difficileClostridioides difficileantibiotic-associated dysbiosislive biotherapeutic product |
| spellingShingle | Anne J. Gonzales-Luna Travis J. Carlson Kevin W. Garey Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies Gut Microbes Microbiome microbiota Clostridium difficile Clostridioides difficile antibiotic-associated dysbiosis live biotherapeutic product |
| title | Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies |
| title_full | Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies |
| title_fullStr | Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies |
| title_full_unstemmed | Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies |
| title_short | Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies |
| title_sort | gut microbiota changes associated with clostridioides difficile infection and its various treatment strategies |
| topic | Microbiome microbiota Clostridium difficile Clostridioides difficile antibiotic-associated dysbiosis live biotherapeutic product |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2023.2223345 |
| work_keys_str_mv | AT annejgonzalesluna gutmicrobiotachangesassociatedwithclostridioidesdifficileinfectionanditsvarioustreatmentstrategies AT travisjcarlson gutmicrobiotachangesassociatedwithclostridioidesdifficileinfectionanditsvarioustreatmentstrategies AT kevinwgarey gutmicrobiotachangesassociatedwithclostridioidesdifficileinfectionanditsvarioustreatmentstrategies |